<DOC>
	<DOCNO>NCT01663402</DOCNO>
	<brief_summary>Primary Objective : To compare effect alirocumab placebo occurrence cardiovascular event ( composite endpoint coronary heart disease ( CHD ) death , non-fatal myocardial infarction ( MI ) , fatal non-fatal ischemic stroke , unstable angina require hospitalization ) patient experience acute coronary syndrome ( ACS ) event 4 52 week prior randomization treat evidence-based medical dietary management dyslipidemia . Secondary Objectives : - To evaluate effect alirocumab secondary endpoint ( CHD event , major CHD event , CV event , composite cause mortality/non-fatal MI/non-fatal ischemic stroke , cause mortality ) . - To evaluate safety tolerability alirocumab . - To evaluate effect alirocumab lipid parameter .</brief_summary>
	<brief_title>ODYSSEY Outcomes : Evaluation Cardiovascular Outcomes After Acute Coronary Syndrome During Treatment With Alirocumab</brief_title>
	<detailed_description>The maximum study duration 64 month , include 4-month run-in period , 60 month randomize treatment period . Number patient age 18 64 year &gt; = 65 year old base number randomize patient ( 18600 patient ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Recently ( &lt; 52 week ) hospitalize ACS . Exclusion criterion : Age &lt; 40 year . ACS event occur 52 week prior randomization visit . LDLC likely &lt; 70 mg/dL ( &lt; 1.81 mmo/L ) evidencebased medical dietary management dyslipidemia . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>